BIOCYTOGEN PHARMA. H YC1 (I54) — Financial Flexibility Index
BIOCYTOGEN PHARMA. H YC1 (I54) has a Financial Flexibility Index of 0.30x as of December 2025. Free cash flow of €458.07 Million (operating CF €370.25 Million minus capex €87.82 Million) represents 0% of total liabilities (€1.54 Billion). Check BIOCYTOGEN PHARMA. H YC1 cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
BIOCYTOGEN PHARMA. H YC1 Financial Flexibility Index (2021–2025)
Historical Financial Flexibility Index trend for BIOCYTOGEN PHARMA. H YC1 across 5 annual periods. For the full cash flow conversion analysis, see BIOCYTOGEN PHARMA. H YC1 cash flow conversion.
Annual Financial Flexibility Index for BIOCYTOGEN PHARMA. H YC1 (2021–2025)
Year-by-year free cash flow to debt coverage for BIOCYTOGEN PHARMA. H YC1. Explore I54 operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (EUR) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.30x | €458.07 Million | €370.25 Million | €1.54 Billion | ▲ +88.2% |
| 2024 | 0.16x | €248.38 Million | €211.25 Million | €1.58 Billion | ▲ +423.0% |
| 2023 | 0.03x | €49.97 Million | €-76.65 Million | €1.66 Billion | ▲ +178.9% |
| 2022 | -0.04x | €-62.99 Million | €-303.27 Million | €1.65 Billion | ▲ +76.0% |
| 2021 | -0.16x | €-167.11 Million | €-365.78 Million | €1.05 Billion | — |